Cognito Reports Pivotal Phase 3 Results for Spectris AD, a Non-Invasive, At-Home Approach for Alzheimer's Treatment, Backed by ADDF Investment

Résumé détaillé
Study misses primary endpoint, but prespecified analysis suggests possible benefit in mild Alzheimer's, pointing to a potential role for devices alongside drugs in future…
Study misses primary endpoint, but prespecified analysis suggests possible benefit in mild Alzheimer's, pointing to a potential role for devices alongside drugs in future treatment
NEW YORK, Nov. 16, 2026 /PRNewswire/ -- Cognito Therapeutics presented results today at the Clinical Trials on Alzheimer's Disease (CTAD) conference from its Phase 3 HOPE study of Spectris AD, an investigational, non-invasive, at-home Alzheimer's therapy platform that uses light and sound stimulation to engage gamma-frequency brain activity. Although the study did not meet its primary endpoint, a prespecified analysis of participants with mild Alzheimer's favored Spectris on measures of thinking and daily function.
"While the HOPE study did not meet its primary endpoint, the signal in the mild Alzheimer's subgroup raises important questions that are worth exploring further," said Laura Nisenbaum, PhD, Interim Chief Science Officer of the ADDF. "Daily function is what patients and families tell us matters most, so it will be important to see whether the early signs of slower decline on that measure in people with mild Alzheimer's hold up as more data become available. A non-invasive option like Spectris, with no potential for drug-drug interactions, could one day play a role in the combination treatment regimens that will be needed to make real progress against Alzheimer's."
In the mild Alzheimer's subgroup, Spectris showed nominally significant slowing of decline on CDR-SB, daily function, and instrumental activities of daily living. The difference in outcomes between participants with mild and moderate disease raises the possibility that earlier intervention may be key to clinical benefit, a hypothesis that future studies will need to test.
Anti-amyloid therapies have established an important foundation for Alzheimer's treatment, but not every patient is a candidate for them.
"Mixed results are part of how science moves forward. For the millions of Alzheimer's patients who are not candidates…
Début de l'article, extrait de PR Newswire. Pour lire la suite, ouvrez l'article chez le média.
MarketNews présente le titre et le résumé publiés par le média. L'article complet se lit sur le site de l'éditeur. (www.prnewswire.com)
